|Bid||0.5201 x 1800|
|Ask||0.5400 x 4000|
|Day's Range||0.5200 - 0.5500|
|52 Week Range||0.4030 - 6.0100|
|Beta (3Y Monthly)||1.78|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Arcadia Biosciences (NASDAQ: RKDA ) shares ...
Recent Clinical Achievements Demonstrate Continued Momentum in the U.S. and Israel TEL AVIV, Israel , Aug. 13, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative ...
Israel-based Cellect, a developer of stem cell production technology, announced Monday that the Data and Safety Monitoring Board recommended dose escalation and the continuation of enrollment for the fourth and final dose cohort in the ongoing Phase 1/2 clinical study of ApoGraft. ApoGraft is a platform or production technology designed to eliminate immune responses in any transplantation of foreign cells and tissues. The determination from the DSMB comes after one-month data from the ninth patient enrolled in the mid-stage trial became available.
In the U.S., the Company moved closer to the U.S. clinical trial as Washington University's Scientific Review Committee (SRC) approved the Company's study, with no comments. This, along with the other milestones that have been achieved by the Company over the past few months demonstrate solid progress and the Company is looking forward to working with its clinical partner and sharing further progress in the coming months. "We are increasingly pleased with our global clinical progress," commented Dr. Shai Yarkoni, Chief Executive Officer. "In Israel, the DSMB's recommendation to proceed to the final cohort of our ApoGraft study without modification furthers us towards meeting our goal of enrolling the final three patients by the end of this year, which reaffirms the positive safety data to date.
TEL AVIV, Israel and ST. LOUIS, Missouri, July 8, 2019 /PRNewswire/ -- As the two organizations move closer to the commencement of the clinical trial to determine the safety and tolerability of the Apograft technology for bone marrow transplantations, Cellect Biotechnology Ltd. (APOP), and Washington University (WU), a leading academic institution based in St. Louis, MO, announced the signing of an Accelerated Clinical Trial Agreement (CTA). Cellect has successfully completed the technology transfer to WU's facility, and results of the in-vivo portion of the toxicology study have shown no signs or symptoms of toxicity. "We are continuing to advance our lead development program, ApoGraft™, and pleased to achieve this milestone with Washington University," commented Dr. Shai Yarkoni, Chief Executive Officer. "We have had ongoing and positive discussions with the U.S. Food and Drug Administration (FDA), and based on its feedback we can bypass further pre-Investigation New Drug (IND) interactions and proceed directly to IND filing.
TEL AVIV, Israel , May 21, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial ...
Following a review of its business, including the status of its clinical and development programs, resources and capabilities, Cellect Biotechnology Ltd. (APOP) plans to explore strategic alternatives focused on maximizing shareholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction involving the Company or its assets. Due to a recent and unanticipated delay in the planned filing of the Company’s Investigational New Drug (IND) application for its human ApoGraft trial in the United States, the Company now believes the trial is expected to commence sometime during the first half of 2020, a delay of up to half a year.
Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today it has received notification from The Nasdaq Stock Market, LLC that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- Further validating its ApoGraft™ technology, Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced positive mid-study data from the Company's Phase I/II study of its ApoGraft™ technology. Both, the principal investigator (PI) and independent data safety monitoring board (DSMB) agree that no serious adverse events (SAEs) reported during the course of the study were related to the ApoGraft™ process.
Milestone Execution Positions the Company for Expedited Progress in 2019 TEL AVIV, Israel , March 18, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of a novel stem cell production ...
NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cellect Biotechnology Ltd. (APOP) is a biotechnology company, focused on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. On March 11, 2019, Cellect Biotechnology, announced preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells.
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.
Results and Validation of ApoGraft technology from a variety of sources could lead to a more cost-effective solution for the cell therapy industry. TEL AVIV, Israel, March 11, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced positive preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells. Results of this third-party study further validate that Cellect's Apograft™ technology significantly improves both proliferation and functional capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem cells originating from bone marrow, peripheral blood, umbilical cord, and adipose tissue.
Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced the closing of its previously announced $6.5 million underwritten public offering of 1,889,000 units, with each unit consisting of one American Depositary Share (ADS) and a warrant to purchase one ADS as well as 2,444,800 pre-funded units, with each pre-funded unit consisting of a pre-funded warrant to purchase one ADS and a warrant to purchase one ADS. In addition, the underwriters partially exercised their overallotment option and purchased an aggregate of 350,000 additional ADS of the Company and additional warrants to purchase 650,070 ADSs of the Company, for total gross proceeds of approximately $7.0 million. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.
A.G.P./Alliance Global Partners is acting as the sole book-running manager for the offering. National Securities Corporation and Dawson James Securities, Inc. are acting as co-managers for the offering. The offering is expected to close on or about February 12, 2019, subject to customary closing conditions.
TEL AVIV, Israel and ST. LOUIS, Feb. 5, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced a collaboration with Washington University, a leading academic institution based in St. Louis, MO, aimed at determining the safety and tolerability in a U.S. Phase I/II study using ApoGraft™ for bone marrow transplantations. The collaboration is led by Dr. John DiPersio, Director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine and President of the American Society for Blood and Marrow Transplantation, and Dr. Mark Schroeder, an expert in bone marrow transplantation in the Division of Oncology at Washington University School of Medicine. This will be the first clinical trial in the U.S. using the Company's ApoGraft stem cell selection technology, which is designed to prevent acute graft-versus-host disease following bone marrow transplantation. Previously, the Company has reported positive safety and tolerability data from an ongoing trial that is being performed outside the U.S., and expects to report additional interim results during the first half of 2019. This open label clinical trial of twelve patients, expected to complete recruitment during the second quarter of 2019, is designed to evaluate the safety and tolerability of the ApoGraft™ process in patients with hematological malignancies who are undergoing an allogeneic hematopoietic stem cell transplantation (HSCT).
Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced it has concluded the scale-up development and manufacturing of clinical grade FasL in collaboration with its outsourced supplier. Based on its process and the results of the ongoing clinical trial, the Company has scaled up manufacturing of FasL for hundreds of personal batches fully scalable to hundreds of thousands of batches for clinical and collaborative purposes. The Company expects to form an alliance of clinical and commercial cell therapy centers using the ApoGraft™ technology.
TEL AVIV, Israel, Jan. 23, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a novel regenerative and cell therapy company with production technology, today provided its milestone targets through the second quarter of 2020. The Company is currently in advanced discussions with a leading academic institution.
Dr. Shai Yarkoni, Cellect CEO commented: "The grant approval by KORIL-RDF acknowledges the commercial and scientific potential that may arise from our collaboration with Cell2in. TEL AVIV, Israel, Dec. 17, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced that KORIL-RDF, has approved Cellect's grant application, submitted with Cell2in, a Korean cell therapy company with whom a collaboration agreement was signed recently.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
TEL AVIV, Israel , Nov. 13, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...
Following US, EU, Russia and South Korean approval, Cellect Technology Patent has now also been approved in Japan and Australia Patent Covers First-in-kind Devices Using Cellect's Flagship Technology, ...
TEL AVIV, Israel, Nov. 1, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP) , a developer of a novel stem cell production technology, announced today its CEO Dr. Shai Yarkoni will present at the 24th Annual Bio Europe Conference which is being held in Copenhagen, Denmark from November 5-7, 2018. Dr. Yarkoni will present as part of the Cell and Gene Therapies track on Tuesday, November 6 at 10:15 am. "Our ApoGraft™ technology is designed to enable stem cell companies around the world to manufacture and perform safer and more cost effective stem cell-based therapeutics.
TEL AVIV, Israel, Oct. 22, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell isolation technology, announced that it has successfully developed for industrialization its first in kind new technology as an integral part of Cellect's ApoTainer™. The new technology utilizes FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell-based products' manufacturing.
Such stem cell enrichment products may create a dramatic change in orthopedic treatments and be used during surgical procedures and under cost effective conditions. TEL AVIV, Israel, Oct. 18, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of stem cell selection technology, announced today that it has achieved positive results on the use of human fat derived stem cells (mesenchymal) treated with the ApoGraft™ process in orthopedic treatments of animals. The study used ApoGraft enriched human mesenchymal stem cells at the time of surgery with the aim of improving the post-surgery healing process.